TTP-HUS Associated with Sunitinib

다국어 초록 (Multilingual Abstract)

Thrombotic thrombocytopenic purpura-hemolytic uremic

syndrome (TTP-HUS) is a rare condition that is severe

and may be fatal. Adverse reactions to drugs increasingly

are reported as probable causes of TTP-HUS.

Many chemotherapeutic agents have also been implicated

in causing TTP-HUS. We reported a woman with

metastatic renal cell carcinoma who presented with TTPHUS

associated with sunitinib. She had gross hematuria

and generalized edema. The hemoglobin concentration

was 8.9 g/dl and the platelet count was 46,000/mm³. Her

reticulocyte count was increased to 4.1% and the peripheral

blood smear revealed red blood cell fragmentation

and spherocytes. The patient completely recovered after

discontinuing the use of sunitinib and undergoing plasmapheresis.

Because of the increasing use of sunitinib in the

treatment of cancer patients, oncologists should be

aware of the possibility of TTP-HUS related to sunitinib,

as early recognition and prompt therapeutic intervention

can be beneficial.

참고문헌 (Reference)

1 Eremina V., "VEGF inhibition and renal thrombotic microangiopathy" 358 : 1129-36, 2008

2 Kapiteijn E., "Sunitinibinduced hypertension, thrombotic microangiopathy and reversibleposterior leukencephalopathy syndrome" 18 : 1745-7, 2007

3 Chow LQ, "Sunitinib: from rational design toclinical efficacy" 25 : 884-96, 2007

4 Frangie C., "Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinomaLancet Oncol" 8 : 177-8, 2007

5 Franchini M., "Reducedvon Willebrand factor-cleaving protease levels in secondarythrombotic microangiopathies and other diseases" 33 : 787-97, 2007

6 Rini BI, "Hypothyroidism in patients with metastatic renal cell carcinomatreated with sunitinib" 99 : 81-3, 2007

7 Zupancic M., "Gemcitabine-associatedthrombotic thrombocytopenic purpura" 8 : 634-41, 2007

8 Rock EP, "Food and Drug Administration drug approvalsummary: Sunitinib malate for the treatment of gastrointestinalstromal tumor and advanced renal cell carcinoma" 12 : 107-13, 2007

9 Dlott JS, "Drug-induced thrombotic thrombocytopenic purpura/hemolyticuremic syndrome" 8 : 102-11, 2004

10 Zakarija A., "Drug-induced thrombotic microangiopathy" 31 : 681-90, 2005

11 Medina PJ, "Drug-associated thromboticthrombocytopenic purpura-hemolytic uremic syndrome" 8 : 286-93, 2001

12 Chu TF, "Cardiotoxicity associated with tyrosinekinase inhibitor sunitinib" 370 : 2011-9, 2007